GB201720119D0 - Prevention and/or treatment of neurodegenerative disease - Google Patents

Prevention and/or treatment of neurodegenerative disease

Info

Publication number
GB201720119D0
GB201720119D0 GBGB1720119.5A GB201720119A GB201720119D0 GB 201720119 D0 GB201720119 D0 GB 201720119D0 GB 201720119 A GB201720119 A GB 201720119A GB 201720119 D0 GB201720119 D0 GB 201720119D0
Authority
GB
United Kingdom
Prior art keywords
prevention
treatment
neurodegenerative disease
neurodegenerative
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1720119.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Howard Foundation Holdings Ltd
Original Assignee
Howard Foundation Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Howard Foundation Holdings Ltd filed Critical Howard Foundation Holdings Ltd
Priority to GBGB1720119.5A priority Critical patent/GB201720119D0/en
Publication of GB201720119D0 publication Critical patent/GB201720119D0/en
Priority to EP18725605.2A priority patent/EP3644979B1/en
Priority to GB1807590.3A priority patent/GB2568986B/en
Priority to JP2020521460A priority patent/JP2021505527A/ja
Priority to NZ761512A priority patent/NZ761512B2/en
Priority to RU2020111305A priority patent/RU2020111305A/ru
Priority to MX2020002458A priority patent/MX2020002458A/es
Priority to SG11202000786RA priority patent/SG11202000786RA/en
Priority to KR1020207007980A priority patent/KR20200095452A/ko
Priority to CA3071786A priority patent/CA3071786C/en
Priority to PCT/GB2018/051255 priority patent/WO2019110951A1/en
Priority to AU2018379644A priority patent/AU2018379644B2/en
Priority to EP25186112.6A priority patent/EP4599891A3/en
Priority to BR112020005132-2A priority patent/BR112020005132A2/pt
Priority to ES18725605T priority patent/ES3047101T3/es
Priority to IE20180146A priority patent/IE87241B1/en
Priority to US15/980,083 priority patent/US10835509B2/en
Priority to US16/426,771 priority patent/US20190307715A1/en
Priority to ZA2020/00558A priority patent/ZA202000558B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1720119.5A 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease Ceased GB201720119D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
ES18725605T ES3047101T3 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
KR1020207007980A KR20200095452A (ko) 2017-12-04 2018-05-10 신경퇴행성 질병의 예방 및/또는 치료
PCT/GB2018/051255 WO2019110951A1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
JP2020521460A JP2021505527A (ja) 2017-12-04 2018-05-10 神経変性疾患の予防及び／又は治療
NZ761512A NZ761512B2 (en) 2018-05-10 Prevention and/or treatment of neurodegenerative disease
RU2020111305A RU2020111305A (ru) 2017-12-04 2018-05-10 Предупреждение и/или лечение нейродегенеративного заболевания
MX2020002458A MX2020002458A (es) 2017-12-04 2018-05-10 Prevencion y/o tratamiento de una enfermedad neurodegenerativa.
SG11202000786RA SG11202000786RA (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
EP18725605.2A EP3644979B1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
CA3071786A CA3071786C (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
GB1807590.3A GB2568986B (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
AU2018379644A AU2018379644B2 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
EP25186112.6A EP4599891A3 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease
BR112020005132-2A BR112020005132A2 (pt) 2017-12-04 2018-05-10 prevenção e/ou tratamento de doença neurodegenerativa
US15/980,083 US10835509B2 (en) 2017-12-04 2018-05-15 Prevention and/or treatment of neurodegenerative disease
IE20180146A IE87241B1 (en) 2017-12-04 2018-05-15 Prevention and/or treatment of neurodegenerative disease
US16/426,771 US20190307715A1 (en) 2017-12-04 2019-05-30 Prevention and/or treatment of neurodegenerative disease
ZA2020/00558A ZA202000558B (en) 2017-12-04 2020-01-28 Prevention and/or treatment of neurodegenerative disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
GB201720119D0 true GB201720119D0 (en) 2018-01-17

Family

ID=60950313

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1720119.5A Ceased GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
GB1807590.3A Active GB2568986B (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1807590.3A Active GB2568986B (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Country Status (15)

Country Link
US (1) US10835509B2 (enExample)
EP (2) EP3644979B1 (enExample)
JP (1) JP2021505527A (enExample)
KR (1) KR20200095452A (enExample)
AU (1) AU2018379644B2 (enExample)
BR (1) BR112020005132A2 (enExample)
CA (1) CA3071786C (enExample)
ES (1) ES3047101T3 (enExample)
GB (2) GB201720119D0 (enExample)
IE (1) IE87241B1 (enExample)
MX (1) MX2020002458A (enExample)
RU (1) RU2020111305A (enExample)
SG (1) SG11202000786RA (enExample)
WO (1) WO2019110951A1 (enExample)
ZA (1) ZA202000558B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106957B1 (fr) * 2020-02-07 2024-05-03 Abdelhadi Zahouani Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris
US12076299B2 (en) * 2020-02-20 2024-09-03 Arjuna Natural Pvt Ltd Composition and method to enhance cognitive support and brain health
WO2022244727A1 (ja) * 2021-05-17 2022-11-24 小野薬品工業株式会社 認知機能を改善するための組成物
JPWO2024143060A1 (enExample) * 2022-12-26 2024-07-04

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121421A2 (en) 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
CA2708258C (en) * 2007-12-17 2017-05-09 Newtricious B.V. Method of producing egg yolk based functional food product and products obtainable thereby
GB201014340D0 (en) 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
TR201809213T4 (tr) * 2011-07-07 2018-07-23 Howard Foundation Holdings Ltd Kamaşma yetersizliğinin iyileştirilmesine yönelik yöntem.
DE212013000066U1 (de) * 2012-07-19 2014-09-25 U.S. Nutraceuticals Llc Dba Valensa International Krillöl und reagierte Astaxanthinzusammensetzung
US20140187648A1 (en) * 2013-01-03 2014-07-03 Howard Foundation Holdings Ltd. Identifying Subjects in Need of Treatment
GB201300055D0 (en) * 2013-01-03 2013-02-20 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
CA2907886A1 (en) * 2013-03-28 2014-10-02 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain
JP6178761B2 (ja) * 2013-07-10 2017-08-09 ライオン株式会社 内服剤
CN109068714A (zh) * 2016-02-22 2018-12-21 新粹尔私人有限公司 用于预防或治疗神经退行性疾病的组合物

Also Published As

Publication number Publication date
GB201807590D0 (en) 2018-06-27
EP4599891A2 (en) 2025-08-13
CA3071786A1 (en) 2019-06-13
EP3644979A1 (en) 2020-05-06
GB2568986A (en) 2019-06-05
IE20180146A1 (en) 2019-06-12
US20190167624A1 (en) 2019-06-06
RU2020111305A (ru) 2022-01-10
JP2021505527A (ja) 2021-02-18
NZ761512A (en) 2024-01-26
US10835509B2 (en) 2020-11-17
SG11202000786RA (en) 2020-06-29
ES3047101T3 (en) 2025-12-03
ZA202000558B (en) 2021-10-27
WO2019110951A1 (en) 2019-06-13
AU2018379644A1 (en) 2020-03-19
BR112020005132A2 (pt) 2020-09-15
KR20200095452A (ko) 2020-08-10
IE87241B1 (en) 2021-07-07
GB2568986B (en) 2019-12-18
MX2020002458A (es) 2020-07-20
EP3644979B1 (en) 2025-08-06
CA3071786C (en) 2023-11-14
AU2018379644B2 (en) 2024-02-08
EP4599891A3 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
ZA201901055B (en) Treatment and prevention of sleep disorders
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
EP3694523A4 (en) METHODS AND SUBSTANCES FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES
ZA202000558B (en) Prevention and/or treatment of neurodegenerative disease
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
IL274588A (en) Methods and preparations for improving lysosome function and treating neurodegenerative disease
PT3558335T (pt) Inibição da caspase-1 e sua utilização na prevenção e tratamento de doenças neurológicas
GB201714307D0 (en) Treatment of neurodegenerative diseases
GB201616009D0 (en) Treatment and/or prevention of sepsis
SG11201704430SA (en) Preventive and/or therapeutic agent of immune disease
EP3137097C0 (en) TREATMENT AND PREVENTION OF ALZHEIMER
PL3197556T3 (pl) KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
GB201615298D0 (en) Treatment and prevention of Malaria
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
PL3137094T3 (pl) Leczenie i profilaktyka choroby alzheimera (ad)
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
LT3137093T (lt) Alzheimerio ligos (ad) gydymas ir prevencija
GB201719969D0 (en) Prevention and/or treatment of neurodegenerative disease
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201714303D0 (en) Treatment of neurodegenerative diseases
PL3490604T3 (pl) Środek leczniczy do leczenia i/lub zapobiegania endometriozie

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)